Bruker Corporation (Nasdaq: BRKR) has entered into a definitive agreement to acquire Chemspeed Technologies AG, a Swiss provider of modular and vendor-agnostic automated laboratory R&D and QC workflow solutions. Chemspeed's focus on modular automation and robotics for chemical research, pharma drug formulation, and materials research aligns with Bruker's strategic move into lab automation, digitalization, and scientific software solutions. This acquisition, anticipated to close in the first half of 2024, supports Bruker's Project Accelerate 2.0 initiative, emphasizing 'Assays, Software, and Aftermarket.' The transaction also brings together Chemspeed's profitable business, generating over $50 million in revenues in 2023, and Bruker's SciY™ platform for software automation in the life science, biopharma, and cleantech sectors. Chemspeed provides flexible automation modules, from bench-top workstations to integrated R&D workflows, setting global standards in lab automation and offering compliance-ready solutions for regulated environments.
Dr. Rolf Gueller, Founder and CEO of Chemspeed, expressed excitement about joining Bruker, anticipating a further boost in automated workflows for customers. Dr. Gueller is set to contribute to Chemspeed customers' success on the Chemspeed Advisory Board. Dr. Falko Busse, President of the Bruker BioSpin Group, highlighted Chemspeed's scalable modularity and flexibility, emphasizing the achievement in lab automation to customize workflows and integrate automation layers efficiently. The addition of Chemspeed to Bruker reflects the commitment to excellence, boasting a wide range of automation solutions and a dedicated approach to customer service.